Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –...

Related Keywords

Australia ,United States ,United Kingdom ,Israel ,Singapore ,China ,Boston ,Massachusetts ,Tsadal ,Kyongsang Bukto ,South Korea ,American ,Richard Paulson ,Reshma Rangwala ,Michael Kauffman ,Sharon Shacham ,Selective Inhibitor Of Nuclear Export ,American Society Of Clinical Oncology ,Linkedin ,Nasdaq ,European Society Of Medical Oncology Virtual Plenary ,Karyopharm Selective Inhibitor Of Nuclear Export ,Menarini Group ,Promedico Ltd ,Committee For Medicinal Products Human Use ,Information Department ,Karyopharm Therapeutics Inc ,Society For Gynecologic Oncology ,Drug Administration ,European Commission ,Prnewswire Karyopharm Therapeutics Inc ,Exchange Commission ,Healthcare Royalty Management ,Antengene Therapeutics ,Achieved First Quarter ,Versus First Quarter ,License Revenues ,Net Product Revenue ,Preliminary Data ,Evaluating Selinexor ,Promising Results ,Pre Specified Exploratory Subgroup Analysis ,Type Endometrial Cancer ,Recent Approvals Received ,Partner Antengene Continues ,Conference Call Scheduled ,Chief Executive Officer ,Antengene Therapeutics Limited ,Mainland China ,American Society ,Clinical Oncology ,European Society ,Medical Oncology ,Virtual Plenary ,Gynecologic Oncology ,Medicinal Products ,Human Use ,Chief Medical ,Chief Scientific Officer ,Senior Clinical Advisor ,Scientific Advisory Board ,Revenue Interest Agreement ,Karyopharm Therapeutics ,Selective Inhibitor ,Nuclear Export ,Medical Information ,Fetal Toxicity ,Private Securities Litigation Reform Act ,Annual Report ,